These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

80 related articles for article (PubMed ID: 32729861)

  • 1. Histone methyltransferase G9a inhibitor-loaded redox-responsive nanoparticles for pancreatic ductal adenocarcinoma therapy.
    Wang JQ; Wang LY; Li SJ; Tong T; Wang L; Huang CS; Xu QC; Huang XT; Li JH; Wu J; Zhao W; Yin XY
    Nanoscale; 2020 Aug; 12(29):15767-15774. PubMed ID: 32729861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A tunable delivery platform to provide local chemotherapy for pancreatic ductal adenocarcinoma.
    Indolfi L; Ligorio M; Ting DT; Xega K; Tzafriri AR; Bersani F; Aceto N; Thapar V; Fuchs BC; Deshpande V; Baker AB; Ferrone CR; Haber DA; Langer R; Clark JW; Edelman ER
    Biomaterials; 2016 Jul; 93():71-82. PubMed ID: 27082874
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Docosahexaenoic acid inhibits the proliferation of Kras/TP53 double mutant pancreatic ductal adenocarcinoma cells through modulation of glutathione level and suppression of nucleotide synthesis.
    Hung WC; Lee DY; Chiang EI; Syu JN; Chao CY; Yang MD; Tsai SY; Tang FY
    PLoS One; 2020; 15(11):e0241186. PubMed ID: 33137095
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epigenetic targeting DNMT1 of pancreatic ductal adenocarcinoma using interstitial control release biodegrading polymer reduced tumor growth through hedgehog pathway inhibition.
    Huang MH; Chou YW; Li MH; Shih TE; Lin SZ; Chuang HM; Chiou TW; Su HL; Harn HJ
    Pharmacol Res; 2019 Jan; 139():50-61. PubMed ID: 30385365
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Deep-Penetrating Triple-Responsive Prodrug Nanosensitizer Actuates Efficient Chemoradiotherapy in Pancreatic Ductal Adenocarcinoma Models.
    Tang X; Du X; Yu Y; Qin M; Qian L; Zhang M; Yang Y; Yu Q; Gan Z
    Small; 2022 Aug; 18(31):e2202834. PubMed ID: 35808966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Delivery of miR-212 by chimeric peptide-condensed supramolecular nanoparticles enhances the sensitivity of pancreatic ductal adenocarcinoma to doxorubicin.
    Chen W; Zhou Y; Zhi X; Ma T; Liu H; Chen BW; Zheng X; Xie S; Zhao B; Feng X; Dang X; Liang T
    Biomaterials; 2019 Feb; 192():590-600. PubMed ID: 30553134
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacological inhibition of ABCC3 slows tumour progression in animal models of pancreatic cancer.
    Adamska A; Domenichini A; Capone E; Damiani V; Akkaya BG; Linton KJ; Di Sebastiano P; Chen X; Keeton AB; Ramirez-Alcantara V; Maxuitenko Y; Piazza GA; De Laurenzi V; Sala G; Falasca M
    J Exp Clin Cancer Res; 2019 Aug; 38(1):312. PubMed ID: 31378204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. SETD5-Coordinated Chromatin Reprogramming Regulates Adaptive Resistance to Targeted Pancreatic Cancer Therapy.
    Wang Z; Hausmann S; Lyu R; Li TM; Lofgren SM; Flores NM; Fuentes ME; Caporicci M; Yang Z; Meiners MJ; Cheek MA; Howard SA; Zhang L; Elias JE; Kim MP; Maitra A; Wang H; Bassik MC; Keogh MC; Sage J; Gozani O; Mazur PK
    Cancer Cell; 2020 Jun; 37(6):834-849.e13. PubMed ID: 32442403
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined Targeting of G9a and Checkpoint Kinase 1 Synergistically Inhibits Pancreatic Cancer Cell Growth by Replication Fork Collapse.
    Urrutia G; Salmonson A; Toro-Zapata J; de Assuncao TM; Mathison A; Dusetti N; Iovanna J; Urrutia R; Lomberk G
    Mol Cancer Res; 2020 Mar; 18(3):448-462. PubMed ID: 31822519
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Histone deacetylase inhibition is synthetically lethal with arginine deprivation in pancreatic cancers with low argininosuccinate synthetase 1 expression.
    Kim SS; Xu S; Cui J; Poddar S; Le TM; Hayrapetyan H; Li L; Wu N; Moore AM; Zhou L; Yu AC; Dann AM; Elliott IA; Abt ER; Kim W; Dawson DW; Radu CG; Donahue TR
    Theranostics; 2020; 10(2):829-840. PubMed ID: 31903153
    [TBL] [Abstract][Full Text] [Related]  

  • 11. KMT2D deficiency enhances the anti-cancer activity of L48H37 in pancreatic ductal adenocarcinoma.
    Li SS; Jiang WL; Xiao WQ; Li K; Zhang YF; Guo XY; Dai YQ; Zhao QY; Jiang MJ; Lu ZJ; Wan R
    World J Gastrointest Oncol; 2019 Aug; 11(8):599-621. PubMed ID: 31435462
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Peptidylarginine Deiminase Inhibitor Application, Using Cl-Amidine, PAD2, PAD3 and PAD4 Isozyme-Specific Inhibitors in Pancreatic Cancer Cells, Reveals Roles for PAD2 and PAD3 in Cancer Invasion and Modulation of Extracellular Vesicle Signatures.
    Uysal-Onganer P; D'Alessio S; Mortoglou M; Kraev I; Lange S
    Int J Mol Sci; 2021 Jan; 22(3):. PubMed ID: 33573274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer.
    Venkannagari S; Fiskus W; Peth K; Atadja P; Hidalgo M; Maitra A; Bhalla KN
    Oncotarget; 2012 Nov; 3(11):1416-27. PubMed ID: 23232026
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting cancer-associated fibroblasts by dual-responsive lipid-albumin nanoparticles to enhance drug perfusion for pancreatic tumor therapy.
    Yu Q; Qiu Y; Li J; Tang X; Wang X; Cun X; Xu S; Liu Y; Li M; Zhang Z; He Q
    J Control Release; 2020 May; 321():564-575. PubMed ID: 32112854
    [TBL] [Abstract][Full Text] [Related]  

  • 15. δ-Tocotrienol, a natural form of vitamin E, inhibits pancreatic cancer stem-like cells and prevents pancreatic cancer metastasis.
    Husain K; Centeno BA; Coppola D; Trevino J; Sebti SM; Malafa MP
    Oncotarget; 2017 May; 8(19):31554-31567. PubMed ID: 28404939
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The therapeutic targeting of the FGFR1/Src/NF-κB signaling axis inhibits pancreatic ductal adenocarcinoma stemness and oncogenicity.
    Lai SW; Bamodu OA; Tsai WC; Chang YM; Lee WH; Yeh CT; Chao TY
    Clin Exp Metastasis; 2018 Oct; 35(7):663-677. PubMed ID: 29987671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Redox-sensitive carrier-free nanoparticles self-assembled by disulfide-linked paclitaxel-tetramethylpyrazine conjugate for combination cancer chemotherapy.
    Zou L; Liu X; Li J; Li W; Zhang L; Fu C; Zhang J; Gu Z
    Theranostics; 2021; 11(9):4171-4186. PubMed ID: 33754055
    [No Abstract]   [Full Text] [Related]  

  • 18. LncRNA PWAR6 regulates proliferation and migration by epigenetically silencing YAP1 in tumorigenesis of pancreatic ductal adenocarcinoma.
    Huang S; Li Y; Hu J; Li L; Liu Z; Guo H; Jiang B; Chen J; Li J; Xiang X; Deng J; Xiong J
    J Cell Mol Med; 2021 May; 25(9):4275-4286. PubMed ID: 33834618
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Verteporfin suppresses cell survival, angiogenesis and vasculogenic mimicry of pancreatic ductal adenocarcinoma via disrupting the YAP-TEAD complex.
    Wei H; Wang F; Wang Y; Li T; Xiu P; Zhong J; Sun X; Li J
    Cancer Sci; 2017 Mar; 108(3):478-487. PubMed ID: 28002618
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
    Watanabe S; Shimada S; Akiyama Y; Ishikawa Y; Ogura T; Ogawa K; Ono H; Mitsunori Y; Ban D; Kudo A; Yamaoka S; Tanabe M; Tanaka S
    Int J Cancer; 2019 Jul; 145(1):192-205. PubMed ID: 30556125
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.